18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicinagl
dc.contributor.authorMoscoso Rial, Alexis
dc.contributor.authorSilva Rodríguez, Jesús
dc.contributor.authorAldrey Vázquez, José Manuel
dc.contributor.authorCortés Hernández, Julia
dc.contributor.authorPías Peleteiro, Juan Manuel
dc.contributor.authorRuibal Morell, Álvaro
dc.contributor.authorAguiar Fernández, Pablo
dc.date.accessioned2022-08-03T08:13:02Z
dc.date.available2022-08-03T08:13:02Z
dc.date.issued2022
dc.description.abstractPurpose: Recent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM). Alzheimer’s disease (AD) is characterized by myelin changes that are believed to occur early in the disease course. Nevertheless, the extent to which demyelination, as measured with Aβ PET, contributes to AD progression remains unexplored. Methods: Participants with concurrent 18F-florbetapir (FBP) PET, MRI, and cerebrospinal fluid (CSF) examinations were included (241 cognitively normal, 347 Aβ-positive cognitively impaired, and 207 Aβ-negative cognitively impaired subjects). A subset of these participants had also available diffusion tensor imaging (DTI) images (n = 195). We investigated cross-sectional associations of FBP retention in the white matter (WM) with MRI-based markers of WM degeneration, AD clinical progression, and fluid biomarkers. In longitudinal analyses, we used linear mixed models to assess whether FBP retention in normal-appearing WM (NAWM) predicted progression of WM hyperintensity (WMH) burden and clinical decline. Results: In AD-continuum individuals, FBP retention in NAWM was (1) higher compared with WMH regions, (2) associated with DTI-based measures of WM integrity, and (3) associated with longitudinal progression of WMH burden. FBP uptake in WM decreased across the AD continuum and with increasingly abnormal CSF biomarkers of AD. Furthermore, FBP retention in the WM was associated with large-calibre axon degeneration as reflected by abnormal plasma neurofilament light chain levels. Low FBP uptake in NAWM predicted clinical decline in preclinical and prodromal AD, independent of demographics, global cortical Aβ, and WMH burden. Most of these associations were also observed in Aβ-negative cognitively impaired individuals. Conclusion: These results support the hypothesis that FBP retention in the WM is myelin-related. Demyelination levels progressed across the AD continuum and were associated with clinical progression at early stages, suggesting that this pathologic process might be a relevant degenerative feature in the disease coursegl
dc.description.peerreviewedSIgl
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was partially supported by the projects RYC-2015/17430 (Ramón y Cajal, Pablo Aguiar), PI19/01315 (ISCIII project), 0624_2IQBIONEURO_6_E and EAPA_791/2018 (UE projects)gl
dc.identifier.citationEuropean Journal of Nuclear Medicine and Molecular Imaging 49, 1242–1253 (2022). https://doi.org/10.1007/s00259-021-05493-ygl
dc.identifier.doi10.1007/s00259-021-05493-y
dc.identifier.essn1619-7089
dc.identifier.urihttp://hdl.handle.net/10347/28997
dc.language.isoenggl
dc.publisherSpringergl
dc.relation.publisherversionhttps://doi.org/10.1007/s00259-021-05493-ygl
dc.rights© The Author(s) 2021, corrected publication 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/gl
dc.rightsAtribución 4.0 Internacional
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject18F-florbetapirgl
dc.subjectAlzheimergl
dc.subjectMyelingl
dc.subjectProgressiongl
dc.subjectWhite mattergl
dc.title18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrumgl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication0365da51-3f8c-4f53-989e-1a2b55bfec3b
relation.isAuthorOfPublication6a1630c3-8a68-4656-9fac-695b76a69303
relation.isAuthorOfPublication.latestForDiscovery0365da51-3f8c-4f53-989e-1a2b55bfec3b

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022_eurjou_moscoso_18Fflorbetapir.pdf
Size:
2.63 MB
Format:
Adobe Portable Document Format
Description: